secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001104659-25-120893
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts CUTX-101 NDA resubmission as Class 1; PDUFA date Jan 14, 2026
-------------------------------------------------------------------------

- FDA accepted NDA resubmission for CUTX-101 (copper histidinate) for Menkes disease; new PDUFA target action date January 14, 2026.
- Prior complete response letter in Sept 2025 cited only cGMP manufacturing observations; no efficacy/safety deficiencies.
- Sentynl (Zydus unit) leads development/commercialization; Cyprium eligible for up to $129M milestones plus PRV if approved.
- CUTX-101 previously granted Priority Review; early treatment showed significant improvement in overall survival.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925120893/0001104659-25-120893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925120893/fbio-20251215x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-120893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer